StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 
 
 
Novartis AG
103.90
+1.07%
 

NVS

 

Novartis AG

$ 103.90

 
+$1.10 | +1.07%
 
 
Open
$ 103.72
 
 
MKT CAP
$ 236.88B
 
High
$ 104.14
 
 
VOL
$ 1.22M
 
Low
$ 103.62
 
 
AVG VOL
$ 1.37M
 
 
 

NVS Stock Analysis

  Login to display Novartis AG (NVS) recommendation from the last 90 days from financial news and social media.
 
 

NVS Total Score

 

Chart

 
 

107.6

98.14

97.87

83.82

 
 
1month
3month
6month
1year
 
Total Return
NVS
vs.
S&P500
 

 
1-week Return
+4.29%
 
+1.17%
 
 
5-week Return
-3.82%
 
+6.44%
 
 
10-week Return
+6.81%
 
+10.09%
 
 
 
 

Strengths

NVS Rewards

 Earnings are forecast to grow

NVS Rewards

 Analysts raised price target

 
 

NVS Risk Level

This Indicator assigning risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
NVS Risk Level
LOW
HIGH

Risk Volatility

 

NVS has Low Risk Level

Click here to check what is your level of risk

 

NVS Analysts Opinion

The company overall standing based on key factors, offering insights into analysts perspectives and market expectations. Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.50
 

NVS Earnings Sentiment

 Below analyst estimate

NVS Earnings Sentiment

 Earnings increase YoY

 
 

Rating

×
 

Rating

NA
 
 

Momentum

×
 

Momentum

3.40
 

NVS Momentum Analysis

 Has been gaining momentum

 

Activity

×
 

Activity

3.96
 
 

Future

×
 

Future

4.25
 

NVS Future Sentiment

 Earnings are forecast to grow

NVS Future Sentiment

 Analysts raised price target

 
 

NVS Analysts Opinion

NVS Analysts opinion is negative and it remained unchanged from the past 3 months

 

NVS Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
86%
Buy
Opinion
Trend
Score
Potential
Score
 
 
NA
60%
100%
 
On Track
On Track
On Track
 

NVS Street Opinion 

NVS Street view is extremely ish and have positive views on the near-term outlook

 

NVS Performance Sentiment

Sentiments overview associated with the company events and the stock performance.
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
Contrasts the positive and negative sentiments surrounding the company performance.
 
86%
9%
Positive
Negative
64 out of 74
events present
7 out of 74
events present
 
 

NVS Earnings

The Trailing Twelve Months (TTM) reflects 12-month period, providing rview of NVS financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
53,073
51,828
52,877
+0.19%
 
 
Cost of Revenue
16,151
15,486
15,867
+0.89%
 
 
Gross Profit
36,922
36,342
37,010
-0.12%
 
 
Operating Expense
27,029
27,145
25,321
+3.32%
 
 
Operating Income
9,893
9,197
11,689
-8.00%
 
 
Net Interest Income
-530
-817
-891
-
 
 
Interest Expense
869
837
811
+3.51%
 
 
Interest Income
514
379
71
+169.06%
 
 
Other Income
-194
-9
15,339
 
 
EPS
-
3.19
10.71
-
 
 
Similar to NVS
Total Score
Close Price
%
Change

AZN

Astrazeneca

3.53

65.83

+2.65%

 

KPTI

Karyopharm Therapeutics

N/A

1.24

+9.73%

 

BMY

Bristol-Myers Squibb

3.33

51.66

+0.64%

 

MOR

MorphoSys AG American

N/A

17.62

-0.51%

 

EVO

Evotec SE American

N/A

7.56

+1.61%

 
 
 
Highlights
Last Modify
Price
% Change

 
Agreements
1 Week Ago
99.05
-0.02%
 
Agreements
2 Weeks Ago
103.46
-0.31%
 
Agreements
3 Weeks Ago
103.72
-1.53%
 
Weak Earnings
3 Weeks Ago
103.47
-3.97%
 
Agreements
2 Month Ago
107.44
-0.17%
 
 

NVS Latest News Feed
































 
 
 
joker
 
 
 
StocksRunner

Explore our NVS Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our NVS Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 

Most Trending

 
 

-2.76%

 
 
 
 
 
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

NVS Rewards

 Earnings are forecast to grow

NVS Rewards

 Analysts raised price target

 
 
 

NVS Risk Level

 
 
 

The Indicator assigning risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
NVS Risk Level
LOW
HIGH

Risk Volatility

 

NVS has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

NVS

 

Novartis AG

$ 103.90

 
+$1.10 | +1.07%
 
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 103.72
 
 
MKT CAP
$ 236.88B
 
High
$ 104.14
 
 
VOL
$ 1.22M
 
Low
$ 103.62
 
 
AVG VOL
$ 1.37M
 
 
 

NVS Analysis

  Sign in to view Novartis AG (NVS) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

107.6

98.14

97.87

83.82

 
 
1month
3month
6month
1year
 
Total Return
NVS
vs.
S&P500
 

 
1-week Return
+4.29%
 
+1.17%
 
 
5-week Return
-3.82%
 
+6.44%
 
 
10-week Return
+6.81%
 
+10.09%
 
 
 

NVS Analysts Opinion

Overall standing by considering key factors, reflecting analysts perspectives and market expectations. Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.50
 

NVS Earnings Sentiment

 Below analyst estimate

NVS Earnings Sentiment

 Earnings increase YoY

 
 

Rating

×
 

Rating

NA
 
 

Momentum

×
 

Momentum

3.40
 

NVS Momentum Sentiment

 Has been gaining momentum

 

Activity

×
 

Activity

3.96
 
 

Future

×
 

Future

4.25
 

NVS Future Sentiment

 Earnings are forecast to grow

NVS Future Sentiment

 Analysts raised price target

 
 

NVS Analysts Opinion

NVS Analysts opinion is negative and it remained unchanged from the past 3 months

 

NVS Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
86%
Buy
Opinion
Trend
Score
Potential
Score
 
 
NA
60%
100%
 
On Track
On Track
On Track
 

NVS Street Opinion 

NVS Street view is extremely ish and have positive views on the near-term outlook

 
NVS Performance Sentiment
Sentiments overview associated with the company events and the stock performance.
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
Contrasts the positive and negative sentiments surrounding the company performance.
 
86%
9%
Positive
Negative
64 out of 74
events present
7 out of 74
events present
 

 

NVS Earnings

The Trailing Twelve Months (TTM) data reflects the most recent 12-month period, providing overview of NVS financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
53,073
51,828
52,877
+0.19%
 
 
Cost of Revenue
16,151
15,486
15,867
+0.89%
 
 
Gross Profit
36,922
36,342
37,010
-0.12%
 
 
Operating Expense
27,029
27,145
25,321
+3.32%
 
 
Operating Income
9,893
9,197
11,689
-8.00%
 
 
Net Interest Income
-530
-817
-891
-
 
 
Interest Expense
869
837
811
+3.51%
 
 
Interest Income
514
379
71
+169.06%
 
 
Other Income
-194
-9
15,339
 
 
EPS
-
3.19
10.71
-
 
 
Highlights
Last Modify
Price
% Change

 
Agreements
1 Week Ago
99.05
-0.02%
 
Agreements
2 Weeks Ago
103.46
-0.31%
 
Agreements
3 Weeks Ago
103.72
-1.53%
 
Weak Earnings
3 Weeks Ago
103.47
-3.97%
 
Agreements
2 Month Ago
107.44
-0.17%
 
 
NVS Latest News Feed

Novartis aiming to develop next-generation weight-loss drugs.

Fri Feb 16, 2024

Activity

Exploring The Competitive Space: Merck &. Co Versus Industry Peers In Pharmaceuticals. In today'.s rapidly changing and fiercely competitive business landscape it is essential for investors and industry enthusiasts to thoroughly analyze companies.

Wed Feb 14, 2024

Activity

NVS Makes Notable Cross Below Critical Moving Average. In trading on Monday shares of Novartis (Symbol: NVS) crossed below their 200 day moving average of $100.42 changing hands as low as $99.48 per share. Novartis shares are currently trad

Mon Feb 12, 2024

Momentum

morphosys adrs gain after definitive merger agreement with novartis disclosed.

Wed Feb 7, 2024

Activity
Momentum

morphosys agrees to be acquired by novartis for eur 2.7 bln. (rttnews) - morphosys (mor) has announced that it reached an agreement with novartis (nvs) based on novartis intention to submit a voluntary public takeover offer for all of morphosys

Tue Feb 6, 2024

Activity
Potential

novartis (nvs) to buy morphosys & add late-stage oncology drug. novartis nvs announced that it will acquire germany-based global biopharmaceutical company morphosys ag mor to expand its oncolog

Tue Feb 6, 2024

Activity

biotech stock morphosys catapults 56% as novartis agrees to buy it for $2.9 billion. novartis agreed late monday to buy morphosys for about $2.9 billion. the cancer-focused biotech stock catapulted to a nearly three-year high. the post biotech stock morph

Tue Feb 6, 2024

Activity

why novartis is going to walk from its acquisition of morphosys. why novartis is going to walk away from its acquisition of morphosys novartis said monday that it intends to buy morphosys for just under $3 billion. the deal will not close. six months from

Tue Feb 6, 2024

Activity

novartis agrees to acquire german blood cancer-drug developer morphosys for €2.7b. monday)a voluntary public takeover offer to acquire

Tue Feb 6, 2024

Activity

morphosys jumps amid report novartis in takeover talks. karyopharm surges in sympathy. morphosys ag (nasdaq:mor) adrs soared 58% amid a report that novartis (nyse:nvs) is in advanced talks to acquire the cancer drugmaker. novartis (nvs) appears to be winn

Mon Feb 5, 2024

Activity

novartis in the lead to acquire cancer drug developer morphosys-sources.

Mon Feb 5, 2024

Activity

novartis to buy morphosys for $2.9 billion. deal seen closing in 1h.

Mon Feb 5, 2024

Activity

novartis acquires cancer drug developer morphosys for $2.9 billion.

Mon Feb 5, 2024

Activity

morphosys jumps amid report novartis in takeover talks. karyopharm surges in sympathy (update).

Mon Feb 5, 2024

Activity

morphosys jumps amid report novartis in advanced talks to takeover.

Mon Feb 5, 2024

Activity

exclusive-novartis in the lead to acquire cancer drug developer morphosys-sources. drug maker novartis ag is in advanced talks to acquire morphosys ag a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion) two people

Mon Feb 5, 2024

Activity

valeo pharma amends agreement with novartis pharmaceuticals canada for (pr)xiidra® in canada and credit facility with sagard healthcare royalty partners lp. /not for distribution to United States news wire services or dissemination in original commercia

Fri Feb 2, 2024

Activity

novartis non-gaap eps of $1.53 misses by $0.13 revenue of $11.42b misses by $350m.

Wed Jan 31, 2024

Earnings

novartis q4 profit surges core eps miss view. sees growth in fy24. updates mid-term outlook. (rttnews) - swiss drug major novartis ag (nvs) reported wednesday that its fourth-quarter net income was $8.48 billion up from last years $1.47 billion.

Wed Jan 31, 2024

Earnings

novartis stock down as q4 core eps miss estimates. sees growth in fy24. (rttnews) - shares of novartis ag were losing more than 4 percent in the morning trading on the switzerland exchange as well as in pre-market activity on the nyse after the

Wed Jan 31, 2024

Earnings
Momentum

novartis (nvs) q4 earnings miss on higher costs sales lag. swiss pharma giant novartis ag nvs reported lower-than-expected results in the fourth quarter of 2023. core earnings (excluding one-ti

Wed Jan 31, 2024

Earnings

earnings outlook for novartis. ) is set to give its latest quarterly earnings report on wednesday 2024-01-31. here'.s what investors need to know before the announcement. analysts estimate that novartis will report an novartis s will hope to hear t

Tue Jan 30, 2024

Activity

top pharma ceo says preparedness for a new pandemic has not improved. vas narasimhan chief executive officer of novartis ag listens during a panel session on the opening day of the world economic forum (wef) in davos switzerland on tuesday jan. 22 2019. v

Tue Jan 16, 2024

Potential

novartis (nvs) stock drops despite market gains: important facts to note. in the latest trading session novartis (nvs) closed at $107.45 marking a -0.14% move from the previous day. the stock f

Fri Jan 12, 2024

Momentum

cytokinetics heart drug is a multi-billion dollar opportunity by 2032 despite novartis setback: analyst. thursday) decided to step back from pursuing the) acquisition dealing a blow to the potential deal with the

Fri Jan 12, 2024

Activity
Potential

novartis ag - adr shares close in on 52-week high - market mover. novartis ag - adr (nvs) shares closed today at 0.2% below its 52 week high of $107.80 giving the company a market cap of $244b. the stock is currently up 6.4% year-to-date up 24.0

Thu Jan 11, 2024

Momentum

novartis (nvs) gains as market dips: what you should know. novartis (nvs) closed the latest trading day at $107.60 indicating a 0.15% change from the previous sessions end. the stock outpaced t

Thu Jan 11, 2024

Momentum

novartis retreats from cytokinetics deal dashing hopes for multi-billion dollar acquisition. ) has decided to step back from pursuing the) acquisition dealing a blow to the potential deal with the

Thu Jan 11, 2024

Activity

novartis said to have backed away from a deal for cytokinetics.

Thu Jan 11, 2024

Activity

cytokinetics (cytk) rises on reports of buyout by novartis. shares of cytokinetics incorporated cytk increased 15.29% after reports of a plausible acquisition by swiss pharma giant novartis nvs

Tue Jan 9, 2024

Activity
Momentum

 
 
 
 
 

Score Tracker

 
 
 
Based on 74 events in the last 90 days from financial news and social media. Last updated Feb 23, 2024 13:28 Wall St. time
 
 

NVS Total Score

 
 
 
 
 
 
 
StocksRunner

Discover NVS Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of NVS. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our NVS Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

NVS Stock trends

NVS Stock performance

NVS Stock analysis

NVS investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker